key: cord-0304782-mwtfhy8n
authors: Vidal-Cruchez, Olivia; Nicolini, Victoria J; Rete, Tifenn; Rezzonico, Roger; Lacoux, Caroline; Fassy, Julien; Jacquet, Karine; Domdom, Marie-Angela; Ventujol, Chloé; Juhel, Thierry; Roméo, Barnabé; Roux, Jérémie; Hubstenberger, Arnaud; Mari, Bernard; Mograbi, Baharia; Hofman, Paul; Brest, Patrick
title: Processing body dynamics drive non-genetic MEK inhibitors tolerance by fine-tuning KRAS and NRAS translation
date: 2022-01-12
journal: bioRxiv
DOI: 10.1101/2021.12.06.471470
sha: a502251449fb20c3301458ebf7946219fee2e2ca
doc_id: 304782
cord_uid: mwtfhy8n

Overactivation of the Mitogen-activated protein kinase (MAPK) pathway is a critical driver of many human cancers. However, therapies targeting this pathway have proven effective in only a few cancers, as cancers inevitably develop resistance. Puzzling observations suggest that MAPK targeting fails in tumors due to early compensatory RAS overexpression, albeit by unexplained mechanisms. We identified a novel mechanism of drug tolerance to MEK inhibitors (MEKi) that involves Processing Bodies (PBs), a membraneless organelle (MLO). MEKi promoted translation of the oncogenes KRAS and NRAS, which in turn triggered BRAF phosphorylation. This overexpression, which occurred in the absence of neotranscription, depended on PB dissolution as the source of the RAS mRNA. Moreover, in response to MEKi removal, the process was dynamic as PBs rapidly reformed and reduced MAPK signaling. These results highlight a dynamic spatiotemporal negative feedback loop of MAPK signaling via RAS mRNA sequestration. Furthermore, we observed a phenotype with a low number of PBs along with strong KRAS and NRAS induction capacities. Overall, we describe a new intricate mechanism involving PBs in the translational regulation of essential cellular signaling pathways like MAPKs, paving the way for future therapies altering MLO and thereby improving targeted cancer therapies.

centrifugation at 12,000g for 15min at 4°C. The aqueous phase was transferred to a fresh 181 tube and the RNA was precipitated overnight at -20°C by mixing with an equal volume of 182 isopropanol, 2ml of glycoblue TM coprecipitant (Thermo Fisher Scientific) and 1/10 183 volume of 3M Na acetate pH 5.2. RNA was pelleted by centrifugation at 12,000g for 15min 184 at 4°C. phosphorylation was almost only achieved when both siRNAs were combined ( Fig. 1D -208 E). Altogether, these results highlight that increasing protein expression of KRAS or NRAS 209 was sufficient to induce phosphorylation of BRAF after MEK inhibition. 210

In this context, we investigated the possible causes for this increase in KRAS and NRAS 211 protein expression. At the transcriptional level, we showed that the mRNA levels of KRAS 212 and NRAS were stable upon PD184352 treatment ( Fig. 2A-B) . Moreover, the PD184352 213 increase in KRAS and NRAS protein levels was maintained in the presence of the 214 transcriptional inhibitor actinomycin D (Fig. 2C, suppl Fig. 1A) . Altogether, these results 215 argue for a posttranscriptional mechanism. 216 Using a ribosome profiling experiment, we showed that the mRNAs of KRAS and NRAS 217 shifted from monosomes to heavy polysome fractions in the presence of PD184352 (Fig.  218   2D ). To confirm an increase in translation, we treated A549 cells with the proteasome 219 inhibitor MG132 to accumulate proteins by blocking their degradation. In cells treated with 220 confirming enhanced translation of KRAS mRNA in the presence of PD184352 (suppl. 222 Fig. 1B-C) . We conclude from these results that the rapid PD184352-induced NRAS and 223 KRAS overexpression is due to an increase in translation rather than transcription. 224

Since it has been reported that KRAS and NRAS mRNAs are accumulated in PBs (3, 19) , 227

we hypothesized that protein overexpression of KRAS and NRAS is associated with the 228 fact that the KRAS and NRAS pool of mRNA previously-stored in PBs has become 229 available for translation. In this context, we analyzed the number and size of cellular PBs Suppl. Fig. 2 ). This overall decrease in the number of PB was not associated with lower 237 DDX6 or LSM14A levels, two proteins required for PB formation (Fig. 3I) , nor with the 238 induction of stress granules (Suppl. Fig. 3) . indicating translational arrest. After removal of the drug, a growth rate comparable to that 248 of untreated cells was re-established, demonstrating the rapid adaptability of cancer cells 249 (Fig. 4E) . Thus, our results provide evidence of two things. Firstly, they show that the high 250 plasticity orchestrated by PBs helps to adjust the translational rate RAS through negative 251 feedback loops. Secondly, they demonstrate that these KRAS and NRAS overexpression 252

can trigger BRAF phosphorylation in the presence of MEKi. This PBs/RAS balance 253 differentiate drug tolerance when compared with growth condition of cancer cells. 254

Next, we tested whether PB dissolution and the associated of KRAS and NRAS 255 overexpression could be corrected prolonged drug treatment. In drug-tolerant A549 cells, 256 after tumor cells were treated with PD184352 at a dose of 2.5µM for 8 weeks, the drug 257 was washed out and the drug-tolerant cells were then cultured for an additional 24h in the 258 presence or absence of PD184352 at indicated concentrations. Figure 5 shows that 259 activation of ERK after MEKi washout was identical to that observed in normal cells for Here, we focused on the early events of drug tolerance. We demonstrated that within 8h, 300 cells were able to establish overexpression of KRAS and NRAS that was independent of 301 de novo transcription and inhibition of protein degradation. Interestingly, we observed that 302 this overexpression persisted for weeks and eventually overcame MAPK inhibition. and NRAS mRNAs (i.e., the length of 5.3kb and 4.3kb, respectively, and the low GC content of their coding region or 3'UTR mRNA, 38% and 44%, respectively) may also 331 contribute to their targeting of PBs(30). Previous studies have shown that KRAS is poorly 332 translated compared to HRAS due to its enrichment in genomically underrepresented or 333 rare codons(31, 32). In our study, we observed that either MEKi-induced dissolution or 334 downregulation of DDX6 were associated with strong translation of KRAS and NRAS 335 mRNAs and overexpression of the corresponding proteins. These results suggest that 336 rare codons, often associated with the presence of an AU-rich third codon, favor the 337 recruitment of mRNA repressors due to slow translational processing, which, however, 338

can be overcome under certain conditions. 339

Overall, these results reveal a novel negative feedback loop involving PBs in the 340 translational control of KRAS and NRAS mRNAs (Suppl Fig. 7) . The type of regulation of 341 the MAPK pathway that we have described here should pave the way for therapies that 342 avert early resistance and achieve drug-tolerant cells before relapse. 343 Quantification of western blot. 601

Western blot quantification of KRAS and NRAS at the indicated time, Results 627 represent the merge of 2 independent experiments C. Resistant cells (PD18_R) were 628 cultured in the absence or presence of PD184352 (2.5µM) and counted at indicated time

Results are representative of 2 independent biological triplicates

A549 wild type (WT) cells, overexpressing a green fluorescent protein (GFP) and a

DDX6-GFP fused protein (DDX6). A. Western blot quantification of KRAS and NRAS at 634 the indicated time, Results represent the merge of 2 independent experiments

C-E. A549 cells were transfected with a siControl (siCTL) or with a siDDX6 637 for 48h. C-D. Western blot quantification of KRAS and NRAS at the indicated time. Results 638 represent the merge of 2 independent experiments. E. Confocal analysis of PBs using 639 anti-LSM14

Negative feedback loop under ERK1/2 phosphorylation is associated with formation of 643

PBs control KRAS and NRAS mRNA translation. PB dissolution 644 under MEKi treatment is associated with enhanced KRAS and NRAS mRNA translation